{"slideshow_credits": null, "snippet": "Men with high-risk cancer who are given hormone therapy for 18 months live just as long as those treated for a more standard 36 months, a study has found.", "abstract": "Study shows that men with high-risk prostate cancer treated with only 18 months of hormone therapy live just as long as those treated for a more standard 36 months; results could mean sparing men months of unpleasant side effects.", "section_name": "Business Day", "print_page": "5", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/02/13/business/prostate-cancer-study-suggests-shorter-treatments.html", "lead_paragraph": "Men with high-risk cancer who are given hormone therapy for 18 months live just as long as those treated for a more standard 36 months, a study has found.", "headline": {"seo": "Prostate Cancer Study Suggests Shorter Treatments", "main": "Study Points to Shorter Treatments for Prostate Cancer", "print_headline": "Study Points to Shorter Prostate Cancer Treatments"}, "_id": "53ed9a7b38f0d864b79c2ceb", "word_count": "577", "multimedia": [], "pub_date": "2013-02-13T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Prostate Cancer", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "2"}], "blog": [], "subsection_name": null, "type_of_material": "News"}